Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. (RUBY) is a publicly traded company in the Unknown sector. Across all available filings, 16 corporate insiders have executed 82 transactions totaling $13.0M, demonstrating a bullish sentiment with $1.5M in net insider flow. The most recent transaction on Feb 24, 2023 involved a sale of 10,385 shares valued at $1.4K.
RUBY Insider Activity Summary
Who Is Buying RUBY Stock?
No significant insider buying has been recorded for RUBY in the recent period.
Who Is Selling RUBY Stock?
No significant insider selling has been recorded for RUBY in the recent period.
Is Rubius Therapeutics, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for RUBY is bullish with an Insider Alignment Score of 56/100 and a net flow of $1.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
RUBY Frequently Asked Questions
Understanding RUBY Insider Activity
Insider trading at Rubius Therapeutics, Inc. (RUBY) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 16 insiders are actively trading RUBY stock, having executed 82 transactions in the past 90 days. The most active insider is Noubar Afeyan (Executive), who has made 3 transactions totaling $6.1M.
Related Tools
Track Rubius Therapeutics, Inc. Insider Activity
Get notified when executives and directors at RUBY file new Form 4 transactions